Login to Your Account

Other News To Note

Friday, October 7, 2011
Unigene Laboratories Inc., of Boonton, N.J., and Nordic Bioscience AS, of Copenhagen, Denmark, are establishing a joint development vehicle (JDV) to advance up to three of Unigene's calcitonin analogues through Phase II proof-of-concept trials for the treatment of Type II diabetes, osteoarthritis and osteoporosis. Unigene and Nordic will each own 50 percent of the joint venture.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription